Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Cash (2016 - 2025)

Historic Change in Cash for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $3.9 million.

  • Voyager Therapeutics' Change in Cash fell 8921.64% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.7 million, marking a year-over-year decrease of 23321.8%. This contributed to the annual value of $3.8 million for FY2024, which is 11278.63% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Change in Cash is $3.9 million, which was down 8921.64% from -$30.8 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Change in Cash peaked at $169.4 million during Q1 2023, and registered a low of -$179.0 million during Q3 2023.
  • Moreover, its 5-year median value for Change in Cash was $3.4 million (2025), whereas its average is -$2.9 million.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 11967333.33% in 2022, then soared by 107286.7% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Change in Cash stood at $6.0 million in 2021, then tumbled by 64.77% to $2.1 million in 2022, then soared by 68.32% to $3.5 million in 2023, then tumbled by 1264.96% to -$41.2 million in 2024, then skyrocketed by 109.54% to $3.9 million in 2025.
  • Its Change in Cash was $3.9 million in Q3 2025, compared to -$30.8 million in Q2 2025 and $3.4 million in Q1 2025.